Your shopping cart is currently empty

Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $80 | In Stock | In Stock | |
| 5 mg | $223 | In Stock | In Stock | |
| 10 mg | $392 | In Stock | In Stock | |
| 25 mg | $668 | In Stock | In Stock | |
| 50 mg | $1,090 | In Stock | In Stock | |
| 100 mg | $1,780 | In Stock | In Stock | |
| 200 mg | $2,380 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $425 | In Stock | In Stock |
| Description | Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
| Targets&IC50 | MCF-7 cells:30 nM, HCC1954 cells:60 nM, PI3Kα:0.038 nM |
| In vitro | METHODS: Cell viability was assayed using Inavolisib (GDC-00777) up to 100 μmol/L in a panel of cancer cell lines. RESULTS Inavolisib (GDC-00777) is a stronger cellular antiproliferative inducer. [1] |
| In vivo | METHODS: p110a protein depletion was studied in a p110a mutant xenograft breast cancer model using Inavolisib (GDC-0077) at a single oral dose of 50 mg/kgDC-0077. RESULTS Inavolisib (GDC-0077) depleted p110a protein expression for up to 8 hours. [1] |
| Synonyms | RG6114, GDC-0077 |
| Molecular Weight | 407.37 |
| Formula | C18H19F2N5O4 |
| Cas No. | 2060571-02-8 |
| Smiles | C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O |
| Relative Density. | 1.63 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 240 mg/mL (589.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (24.55 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.